| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |
Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells
From the Second Department of Internal Medicine (Y.O., N.A., M.K.), Gunma University School of Medicine, Maebashi, Gunma, Japan; and Department of Cardiovascular Medicine (R.N.), Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Correspondence to Masahiko Kurabayashi, MD, PhD, Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15 Showa-machi, Maebashi, 371-8511, Japan. E-mail mkuraba{at}med.gunma-u.ac.jp
Peroxisome proliferator-activated receptor
(PPAR
) is a member of the nuclear receptor superfamily that acts as a key player in adipocyte differentiation, glucose metabolism, and macrophage differentiation. Osteopontin (OPN), a component of extracellular matrix, is elevated during neointimal formation in the vessel wall and is synthesized by macrophages in atherosclerotic plaques. In the present study, we investigated the molecular mechanisms regulating OPN gene expression by PPAR
in THP-1 cells, a cell line derived from human monocytic leukemia cells. Northern and Western blot analyses showed that exposure of THP-1 cells to PMA (phorbol 12-myristate 13-acetate) increases OPN mRNA and protein levels in a time-dependent manner. PMA-induced OPN expression was significantly decreased by troglitazone (Tro) and other PPAR
ligands. Transient transfection assays of the human OPN promoter/luciferase construct showed that PPAR
represses OPN promoter activity, and the PPAR
-responsive region within the OPN promoter lies between -1000 and -970 relative to the transcription start site. Site-specific mutation analysis and electrophoretic mobility shift assays indicated that a homeobox-like A/T-rich sequence between -990 and -981, which functions as a binding site for PMA-induced nuclear factors other than PPAR
, mediates the repression of OPN expression by Tro. Furthermore, concatenated A/T-rich sequences conferred the PPAR
responsiveness on the heterologous promoter. Taken together, these data suggest that PPAR
ligand inhibits OPN gene expression through the interference with the binding of nuclear factors to A/T-rich sequence in THP-1 cells.
Key Words: peroxisome proliferator-activated receptor
osteopontin macrophage transcription factors
This article has been cited by other articles:
![]() |
A. Mencarelli, B. Renga, M. Migliorati, S. Cipriani, E. Distrutti, L. Santucci, and S. Fiorucci The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis J. Immunol., November 15, 2009; 183(10): 6657 - 6666. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kis, C. Murdoch, M. Zhang, A. Siva, S. Rodriguez-Cuenca, S. Carobbio, A. Lukasik, M. Blount, S. O'Rahilly, S. L. Gray, et al. Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice Eur J Heart Fail, June 1, 2009; 11(6): 533 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bertola, V. Deveaux, S. Bonnafous, D. Rousseau, R. Anty, A. Wakkach, M. Dahman, J. Tordjman, K. Clement, S. E. McQuaid, et al. Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid Obesity Diabetes, January 1, 2009; 58(1): 125 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Caglayan, B. Stauber, A. R. Collins, C. J. Lyon, F. Yin, J. Liu, S. Rosenkranz, E. Erdmann, L. E. Peterson, R. S. Ross, et al. Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor {gamma} in Cardiac Fibrosis Diabetes, September 1, 2008; 57(9): 2470 - 2479. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1050 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Desmarais, F. L Lopes, H. Zhang, S. K Das, and B. D Murphy The Peroxisome Proliferator-Activated Receptor Gamma Regulates Trophoblast Cell Differentiation in Mink (Mustela vison) Biol Reprod, November 1, 2007; 77(5): 829 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakamachi, T. Nomiyama, F. Gizard, E. B. Heywood, K. L. Jones, Y. Zhao, L. Fuentes, K. Takebayashi, Y. Aso, B. Staels, et al. PPAR{alpha} Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes Diabetes, June 1, 2007; 56(6): 1662 - 1670. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ogawa, J. F. Stone, Y. Takata, F. Blaschke, V. H. Chu, D. A. Towler, R. E. Law, W. A. Hsueh, and D. Bruemmer Liver X Receptor Agonists Inhibit Cytokine-Induced Osteopontin Expression in Macrophages Through Interference With Activator Protein-1 Signaling Pathways Circ. Res., April 15, 2005; 96(7): e59 - e67. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lammi, J. Huppunen, and P. Aarnisalo Regulation of the Osteopontin Gene by the Orphan Nuclear Receptor NURR1 in Osteoblasts Mol. Endocrinol., June 1, 2004; 18(6): 1546 - 1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. El-Tanani, A. Platt-Higgins, P. S. Rudland, and F. C. Campbell Ets Gene PEA3 Cooperates with {beta}-Catenin-Lef-1 and c-Jun in Regulation of Osteopontin Transcription J. Biol. Chem., May 14, 2004; 279(20): 20794 - 20806. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Hsueh and D. Bruemmer Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease Hypertension, February 1, 2004; 43(2): 297 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1927 - 1939. [Full Text] [PDF] |
||||
![]() |
M. Bidder, J.-S. Shao, N. Charlton-Kachigian, A. P. Loewy, C. F. Semenkovich, and D. A. Towler Osteopontin Transcription in Aortic Vascular Smooth Muscle Cells Is Controlled by Glucose-regulated Upstream Stimulatory Factor and Activator Protein-1 Activities J. Biol. Chem., November 8, 2002; 277(46): 44485 - 44496. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takata, Y. Kitami, Z.-H. Yang, M. Nakamura, T. Okura, and K. Hiwada Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-{delta} and Peroxisome Proliferator-Activated Receptor-{gamma} Circ. Res., September 6, 2002; 91(5): 427 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Demer Adipose Rex: Fat and Fats That Rule Differentiation Circ. Res., February 22, 2002; 90(3): 241 - 243. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |